AN ANIMAL MODEL OF NATURALLY OCCURRING TUMOR IMMUNITY
天然肿瘤免疫的动物模型
基本信息
- 批准号:6522882
- 负责人:
- 金额:$ 4.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-08-15 至
- 项目状态:未结题
- 来源:
- 关键词:antitumor antibody autoimmunity autologous transplantation breast neoplasms cerebellar disorders cytotoxic T lymphocyte disease /disorder model enzyme linked immunosorbent assay genetically modified animals helper T lymphocyte laboratory mouse natural killer cells neoplasm /cancer immunology neuroimmunomodulation tumor antigens
项目摘要
Paraneoplastic cerebellar degeneration (PCD) provides an important and unique example of naturally occurring breast tumor immunity in humans. PCD is characterized by a high titer antibody directed against a tumor antigen termed cdr2 that is normally expressed in the cerebellum. PCD patients develop an effective immune response to their tumors, and then come to clinical attention with severe neurologic dysfunction. It is proposed that the immune system initiates PCD when cdr2 is recognized as a foreign antigen in breast or ovarian tumors. We have hypothesized that the tumor immunity and neuronal destruction that occurs in PCD is not a result of antibodies against cdr2, but instead results from cytotoxic T cells (CTLs) that kill cdr2 expressing cells. This hypothesis is based in part on the failure of investigators to create an animal model of PCD by inducing cdr2 antibodies, and in part on our finding of cdr2-specific CTLs capable of killing tumors in PCD patients. We propose to test this hypothesis and deepen our understanding of breast tumor immunity by generating an animal model of PCD. Since we also find cdr2 expression in breast tumors obtained from neurologically normal individuals, our studies provide a new and important approach to breast cancer immunity in humans.
副肿瘤性小脑变性(PCD)为人类自然发生的乳腺肿瘤免疫提供了一个重要而独特的例子。PCD的特征是针对一种通常在小脑表达的名为CDR2的肿瘤抗原产生高滴度抗体。PCD患者对肿瘤产生有效的免疫反应,然后出现严重的神经功能障碍。当CDR2被认为是乳腺或卵巢肿瘤中的外来抗原时,有人认为是免疫系统启动了PCD。我们假设PCD中发生的肿瘤免疫和神经元破坏不是抗CDR2抗体的结果,而是杀死表达CD2的细胞的细胞毒性T细胞(CTL)的结果。这一假说部分是基于研究人员未能通过诱导cdr2抗体来创建PCD的动物模型,部分是基于我们发现的cdr2特异性CTL能够杀死PCD患者的肿瘤。我们建议通过建立PCD的动物模型来检验这一假说,并加深我们对乳腺肿瘤免疫的理解。由于我们也发现CDR2在神经正常个体的乳腺肿瘤中表达,我们的研究为人类乳腺癌免疫提供了一种新的和重要的方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Matthew L Albert其他文献
Signal 0 for guided priming of CTLs: NKT cells do it too
细胞毒性 T 淋巴细胞(CTLs)引导启动的信号 0:自然杀伤 T 细胞(NKT 细胞)也这样做
- DOI:
10.1038/ni0410-284 - 发表时间:
2010-04-01 - 期刊:
- 影响因子:27.600
- 作者:
Philippe Bousso;Matthew L Albert - 通讯作者:
Matthew L Albert
Matthew L Albert的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Matthew L Albert', 18)}}的其他基金
EFFECTIVE TUMOR IMMUNOTHERAPY IN TRANSITIONAL CELL CARCINOMA OF THE BLADDER
膀胱移行细胞癌的有效肿瘤免疫治疗
- 批准号:
7207016 - 财政年份:2005
- 资助金额:
$ 4.62万 - 项目类别:
Effective Tumor Immunotherapy in Transitional Cell Carc
移行细胞癌的有效肿瘤免疫治疗
- 批准号:
7041514 - 财政年份:2003
- 资助金额:
$ 4.62万 - 项目类别:
AN ANIMAL MODEL OF NATURALLY OCCURRING TUMOR IMMUNITY
天然肿瘤免疫的动物模型
- 批准号:
6402528 - 财政年份:2001
- 资助金额:
$ 4.62万 - 项目类别:
AN ANIMAL MODEL OF NATURALLY OCCURRING TUMOR IMMUNITY
天然肿瘤免疫的动物模型
- 批准号:
6209844 - 财政年份:2000
- 资助金额:
$ 4.62万 - 项目类别:
相似海外基金
Thymus antibody-secreting cells: major players in autoimmunity.
胸腺抗体分泌细胞:自身免疫的主要参与者。
- 批准号:
502578 - 财政年份:2024
- 资助金额:
$ 4.62万 - 项目类别:
B cell development, autoimmunity and immune regulation
B 细胞发育、自身免疫和免疫调节
- 批准号:
MR/Y033701/1 - 财政年份:2024
- 资助金额:
$ 4.62万 - 项目类别:
Research Grant
Applying advanced understanding of CTLA-4 function to optimise therapies for autoimmunity
应用对 CTLA-4 功能的深入理解来优化自身免疫疗法
- 批准号:
MR/Y001273/1 - 财政年份:2024
- 资助金额:
$ 4.62万 - 项目类别:
Research Grant
MUC16 (CA125) mutations promote fibrosis and autoimmunity in systemic sclerosis
MUC16 (CA125) 突变促进系统性硬化症的纤维化和自身免疫
- 批准号:
478933 - 财政年份:2023
- 资助金额:
$ 4.62万 - 项目类别:
Operating Grants
Development of serologic test for early risk stratification of islet autoimmunity in genetically predisposed T1D individuals
开发用于遗传易感性 T1D 个体胰岛自身免疫早期风险分层的血清学检测
- 批准号:
10760885 - 财政年份:2023
- 资助金额:
$ 4.62万 - 项目类别:
Mechanisms of New-Onset Autoimmunity/Longitudinal Immune Systems Analysis (MONA-LISA)
新发自身免疫/纵向免疫系统分析(MONA-LISA)的机制
- 批准号:
10655219 - 财政年份:2023
- 资助金额:
$ 4.62万 - 项目类别:
Autoimmunity-Associated B Cells in Lupus Nephritis
狼疮性肾炎中自身免疫相关的 B 细胞
- 批准号:
10582053 - 财政年份:2023
- 资助金额:
$ 4.62万 - 项目类别:
Heparan sulfate as a platform to boost regulatory T cell suppression of autoimmunity
硫酸乙酰肝素作为增强调节性 T 细胞抑制自身免疫的平台
- 批准号:
490663 - 财政年份:2023
- 资助金额:
$ 4.62万 - 项目类别:
Operating Grants
The interplay of sex hormones and chromosomes dictates pathogenicity in progressive CNS autoimmunity.
性激素和染色体的相互作用决定了进行性中枢神经系统自身免疫的致病性。
- 批准号:
488982 - 财政年份:2023
- 资助金额:
$ 4.62万 - 项目类别:
Operating Grants
Understanding autoimmunity: Why do B cells sometimes attack our tissues instead of protecting us from infections?
了解自身免疫:为什么 B 细胞有时会攻击我们的组织而不是保护我们免受感染?
- 批准号:
2889164 - 财政年份:2023
- 资助金额:
$ 4.62万 - 项目类别:
Studentship














{{item.name}}会员




